Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €14.63 EUR
Change Today +0.235 / 1.63%
Volume 0.0
3O8 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 1:48 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (3O8) Snapshot

Open
€14.39
Previous Close
€14.40
Day High
€14.85
Day Low
€14.10
52 Week High
03/5/15 - €24.52
52 Week Low
10/29/14 - €8.96
Market Cap
553.5M
Average Volume 10 Days
250.0
EPS TTM
--
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (3O8)

omeros corp (3O8) Related Bloomberg News

View More Bloomberg News

omeros corp (3O8) Related Businessweek News

No Related Businessweek News Found

omeros corp (3O8) Details

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The company’s clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

103 Employees
Last Reported Date: 03/16/15
Founded in 1994

omeros corp (3O8) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $684.1K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $285.0K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $352.6K
Compensation as of Fiscal Year 2014.

omeros corp (3O8) Key Developments

FDA Grants Fast Track to Omeros' Complement Inhibitor OMS721 for aHUS

Omeros Corporation announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. Omeros is currently evaluating the drug in a Phase 2 clinical trial for the treatment of aHUS and other thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. Earlier this year, Omeros announced positive data from the Phase 2 trial and commencement of an investigator-requested compassionate use program for OMS721 to allow extended treatment of patients who completed the trial's four-week dosing. Recent efficacy and safety data from the ongoing Phase 2 clinical trial were submitted to the FDA in the company's request for Fast Track status for OMS721. FDA's Fast Track program facilitates the development of drugs intended to treat serious or life-threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval. Many drugs that receive Fast Track designation are also considered appropriate to receive Priority Review, and their respective New Drug Applications (NDAs) may be accepted by the FDA as a 'rolling submission' in which portions of an NDA are reviewed before the complete application is submitted. Priority Review and rolling submission can each provide further acceleration of FDA's approval process. The Phase 2 clinical trial evaluating OMS721 in the treatment of TMAs, including aHUS, thrombotic thrombocytopenic purpura and human stem cell transplant-related TMAs, is ongoing in multiple sites in both the United States and Europe. The majority of the patients enrolled to date are those suffering from aHUS.

Omeros Corporation Appoints Rajiv Shah to Board of Directors

Omeros Corporation announced that Rajiv Shah, M.D., recent Administrator of the United States Agency for International Development, has been appointed to serve on the company's board of directors. From 2010 to 2015, Dr. Shah served as Administrator of USAID. From 2009 to 2010, Dr. Shah served as the Under Secretary for Research, Education and Economics and Chief Scientist at the U.S. Department of Agriculture.

Omeros Corporation Enters into an Exclusive License Agreement with Affiliates of Fagron NV for Commercialization of OMS103

Omeros Corporation announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery. OMS103, added to standard irrigation solution used in arthroscopy, is Omeros' proprietary PharmacoSurgery® product designed to provide a multimodal approach to block preemptively the inflammatory cascade induced by arthroscopic surgical procedures. Nearly five million arthroscopic procedures are projected to be performed in the U.S. in 2015. Under the terms of the license agreement, Omeros granted Fagron an exclusive license to the OMS103 intellectual property, manufacturing information, and clinical data in the United States. In exchange for the U.S. license, Fagron will pay Omeros a substantial majority share of the gross revenues generated from sales of OMS103 with Omeros also receiving a minimum revenue per vial sold. In addition, Fagron will pay Omeros up to an aggregate total of $10 million in commercial milestones, some of which will be received by Omeros as revenue-share enhancement on early sales. Fagron is obligated to meet performance diligence requirements including the commencement of sales of OMS103 in 2015, to bear all sales and marketing costs, and to meet annual sales volume minimums. In addition to transferring the manufacturing and clinical information related to OMS103, Omeros is obligated to provide Fagron with introductions to arthroscopy thought leaders and assistance in understanding the therapeutic field as well as administration methods and to provide Fagron for 12 months with reasonable access to Omeros personnel to respond to any queries regarding the clinical and manufacturing data. Omeros will incur no further development costs, other than maintaining the licensed intellectual property, in connection with OMS103. The licensing agreement also contemplates potential partnerships for additional products from Omeros' PharmacoSurgery platform.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3O8:GR €14.63 EUR +0.235

3O8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3O8.
View Industry Companies
 

Industry Analysis

3O8

Industry Average

Valuation 3O8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 710.7x
Price/Book 27.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 612.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.